



903  
1645  
P#9  
JUN 26 2002

UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-192)

PATENT

RECEIVED

In the Application of:

Progulske-Fox, et al.

Serial No.: 09/849,115

Filed: May 5, 2001

For: Methods and Compositions for  
Angioproliferative Disorder Treatment

Art Unit: 1645

Examiner: To be assigned

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Asst. Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Information Disclosure Statement;
  - b) PTO Form 1449 and 29 cited references;
  - c) Return postcard
2. With respect to fees:
  - a) It is believed no fee is due at this time.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on June 19, 2002.

Date: June 19, 2002

Respectfully submitted,

Lisa M.W. Hillman

Registration No. 43,673



UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-192)

RECEIVED

PATENT JUN 26 2002

TECH CENTER 1600/2900

In the Application of:

**Progulske-Fox, et al.**

Serial No.: **09/849,115**

Filed: **May 5, 2001**

For: **Methods and Compositions for  
Angioproliferative Disorder Treatment**

Art Unit: 1645

Examiner: To be assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is indented as to the relative

importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

### **CITED REFERENCES**

#### **Other Documents**

1. Fidler, et al., "*The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis*", *Cell*, Vol. 79, p. 185-188, minireview, 1994
2. O'Reilly, et al., "*Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma*", *Cell*, Vol. 79, p. 315-328, 1994
3. Aducse-Opoku, et al., "*The Tla Protein of Porphyromonas gingivalis W50: a Homolog of the RI Protease Precursor (PrpRI) is an Outer Membrane Receptor Required for Growth on Low Levels of Hemin*", *Journal of Bacteriology*, Vol. 179, No. 15, p. 4778-4788, 1997
4. Nishikata, et al., "*Characterization of Porphyromonas (Bacteroides) Gingivalis Hemagglutinin as a Protease*", *Biochemical and Biophysical Research Communications*, Vol. 178, No. 1, p. 336-342, 1991
5. Hashizume, et al., "*Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness*", *American Journal of Pathology*, Vol. 156, No. 4, p. 1363-1380, 2000
6. Yeh, et al., "*Rhodostomin, A Snake Venom Disintegrin, Inhibits Angiogenesis Elicited by Basic Fibroblast Growth Factor and Suppresses Tumor Growth by a Selective  $\alpha_v\beta_3$  Blockade of Endothelial Cells*", *Molecular Pharmacology*, Vol. 59, No. 5, p. 1333-1342, 2001
7. Rangarajan, et al., "*The prpRI and prR2 arginine-specific protease genes of Porphyromonas gingivalis W50 produce five biochemically distinct enzymes*", *Molecular Microbiology*, 23(5), p. 955-965, 1997
8. Herlyn, "*Endothelial Cells as Targets for Tumor Therapy*", Editorial, *Journal of Immunotherapy*, 22(3):185, 1999
9. Curtis, et al., "*Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis*", *J. Periodont. Res.*, 34, pp. 464-472, 1999


10. Han, et al., "*The Hemagglutinin Gene A (hagA) or Porphyromonas gingivalis 381 contains four Large, Contiguous, Direct Repeats*", *Infection and Immunity*, Vol. 64, No. 10, p. 4000-4007, 1996
11. GenBank Accession number X82680
12. GenBank Accession number U15282
13. GenBank Accession number D26470
14. GenBank Accession number L26341
15. GenBank Accession number L27483
16. GenBank Accession number AF026946
17. GenBank Accession number A55426
18. GenBank Accession number AF007124
19. GenBank Accession number U85038
20. GenBank Accession number D64081
21. GenBank Accession number U75366
22. GenBank Accession number U54691
23. GenBank Accession number D83258
24. GenBank Accession number U42210
25. GenBank Accession number AF017059
26. GenBank Accession number U68468
27. GenBank Accession number Y07618
28. GenBank Accession number S75942

29. GenBank Accession number M83096

Respectfully submitted,

Date: June 14, 2002

by:

  
**Lisa M. W. Hillman**  
Reg. No. 43,673